Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Santarus initiates enrollment in UCERIS Phase IIIb study for ulcerative colitis

Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.

13 Feb 2012

RUMC sponsors Nutritional Medicine workshop

Rush University Medical Center is sponsoring a Nutritional Medicine workshop March 15 to 16, 2012, that features internationally-renowned faculty who are leaders in research in nutritional medicine.

13 Feb 2012

Ironwood prices public offering of 5,250,000 shares of common stock

Ironwood Pharmaceuticals, Inc. announced today the pricing of an underwritten public offering of 5,250,000 shares of its Class A common stock at a price of $15.09 per share to the public. All of the shares are being offered by Ironwood.

9 Feb 2012

Now on stands - Inhaled caffeine

A Harvard professor has come up with a device that helps people inhale their caffeine from a lipstick-sized tube. Critics say the novel product, called “AeroShot,” is not without its risks. The product went on the market late last month in Massachusetts and New York, and is also available in France. A single unit costs $2.99 at convenience, mom-and-pop, liquor and online stores.

9 Feb 2012

Patients with GERD benefit from radiofrequency ablation

Heartburn. Acid reflux, GERD. They're different terms for the same type of condition - stomach acid used for digestion travels back up the esophagus, the "food pipe" that connects your throat to your stomach.

9 Feb 2012

Study implicates 'arms race' between genes and germs

Biologists have found new evidence of why mice, people and other vertebrate animals carry thousands of varieties of genes to make immune-system proteins named MHCs--even though some of those genes make vertebrate animals susceptible to infections and to autoimmune diseases.

9 Feb 2012

Cirrhosis patients with low musle mass more apt to die

Medical researchers at the University of Alberta reviewed the medical records of more than 100 patients who had a liver scarring condition and discovered those who were losing muscle were more apt to die while waiting for a liver transplant. These cirrhosis patients were placed at a lower spot on the transplant list because they had a higher functioning liver and were seemingly less sick than others with the same condition, based on scoring systems physicians commonly use today.

8 Feb 2012

Takeda launches EDARBYCLOR in the U.S. for treatment of hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., announced EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is now available by prescription in U.S. pharmacies for the treatment of hypertension to lower blood pressure in adults.

6 Feb 2012

Binge drinking and moderate drinking do not differ in risk for ischemic heart disease or mortality

Most studies have found that binge drinking is associated with a loss of alcohol's protective effect against ischemic heart disease (IHD) and most studies have found an increase of coronary risk among binge drinkers.

3 Feb 2012

$Heart burn drugs and hip fractures in postmenopausal women smokers: Study establishes link$

Heart burn drugs and hip fractures in postmenopausal women smokers: Study establishes link

A new study shows that postmenopausal women with a history of smoking who take heartburn drugs called proton pump inhibitors (PPIs) for two years or longer may be more likely to sustain a hip fracture. The risk rises with longer use say researchers. But the risk does disappear after women stop taking these drugs for two years. Further women who never smoked were not at increased risk for hip fracture even if they took PPIs regularly, the study showed. The new findings appear in the journal BMJ.

2 Feb 2012

Takeda, SPI announce that lubiprostone phase 3 trial on OBD meets primary endpoint

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.

2 Feb 2012

Study identifies norovirus as major cause of all infection outbreaks in U.S. hospitals

Norovirus, a pathogen that often causes food poisoning and gastroenteritis, was responsible for 18.2 percent of all infection outbreaks and 65 percent of ward closures in U.S. hospitals during a two-year period, according to a new study published in the February issue of the American Journal of Infection Control (AJIC), the official publication of APIC - the Association for Professionals in Infection Control and Epidemiology.

1 Feb 2012

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors.

1 Feb 2012

Tobacco smoking may increase risk of esophageal cancer in Barrett's patients

Barrett's esophagus (BE) patients who smoke tobacco are at a two-fold increased risk of developing esophageal cancer, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. BE patients who smoke also double their risk for developing advanced precancerous cells.

31 Jan 2012

Study: Live liver donor transplantation safer than previously believed

People who donate a portion of their livers for transplant to a relative or friend whose liver is failing can generally expect to live long, healthy lives and recover safely from the donation surgery, Johns Hopkins researchers have found.

27 Jan 2012

Strong link between high HuR protein levels and malignancy of HCC

Researchers at CIC Biogune, the Cooperative Centre for Research into Biosciences and led by Dr. Maria Luz Martinez Chantar, have found a strong relationship between high levels of Hu antigen R (HuR) protein and the malignancy of Hepatocellular Carcinoma, through a novel molecular process in the investigation of this pathology and known as neddylation.

27 Jan 2012